Pharmacology and clinical experience with simvastatin

David C Hess, S. C. Fagan

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Simvastatin (Zocor™, Merck) is a safe and effective 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Simvastatin potently lowers total and low density lipoprotein (LDL) cholesterol. Simvastatin was the first cholesterol-lowering agent that reduced total mortality in a randomised clinical trial. Simvastatin is effective at reducing total mortality, myocardial infarction, coronary mortality and the incidence of stroke or transient ischemic attack in patients with coronary heart disease and hypercholesterolemia. Simvastatin, like other statins, also has non-lipid mechanisms of action. These include anti-inflammatory effects, antiproliferative effects on smooth muscle cells and an upregulation of endothelial nitric oxide synthase. Overall, simvastatin has an excellent safety profile. Simvastatin, along with other statins, has made a significant impact on the morbidity and mortality from coronary heart disease.

Original languageEnglish (US)
Pages (from-to)153-163
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume2
Issue number1
DOIs
StatePublished - May 22 2001

Fingerprint

Simvastatin
Clinical Pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mortality
Coronary Disease
Nitric Oxide Synthase Type III
Transient Ischemic Attack
Hypercholesterolemia
LDL Cholesterol
Smooth Muscle Myocytes
Oxidoreductases
Anti-Inflammatory Agents
Up-Regulation
Randomized Controlled Trials
Stroke
Myocardial Infarction
Cholesterol
Morbidity
Safety
Incidence

Keywords

  • Atherosclerosis
  • LDL-cholesterol
  • Myocardial infarction
  • Simvastatin
  • Stroke

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacology and clinical experience with simvastatin. / Hess, David C; Fagan, S. C.

In: Expert Opinion on Pharmacotherapy, Vol. 2, No. 1, 22.05.2001, p. 153-163.

Research output: Contribution to journalArticle

@article{26dfe25b83244ab589ced47d216912f4,
title = "Pharmacology and clinical experience with simvastatin",
abstract = "Simvastatin (Zocor™, Merck) is a safe and effective 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Simvastatin potently lowers total and low density lipoprotein (LDL) cholesterol. Simvastatin was the first cholesterol-lowering agent that reduced total mortality in a randomised clinical trial. Simvastatin is effective at reducing total mortality, myocardial infarction, coronary mortality and the incidence of stroke or transient ischemic attack in patients with coronary heart disease and hypercholesterolemia. Simvastatin, like other statins, also has non-lipid mechanisms of action. These include anti-inflammatory effects, antiproliferative effects on smooth muscle cells and an upregulation of endothelial nitric oxide synthase. Overall, simvastatin has an excellent safety profile. Simvastatin, along with other statins, has made a significant impact on the morbidity and mortality from coronary heart disease.",
keywords = "Atherosclerosis, LDL-cholesterol, Myocardial infarction, Simvastatin, Stroke",
author = "Hess, {David C} and Fagan, {S. C.}",
year = "2001",
month = "5",
day = "22",
doi = "10.1517/14656566.2.1.153",
language = "English (US)",
volume = "2",
pages = "153--163",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Pharmacology and clinical experience with simvastatin

AU - Hess, David C

AU - Fagan, S. C.

PY - 2001/5/22

Y1 - 2001/5/22

N2 - Simvastatin (Zocor™, Merck) is a safe and effective 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Simvastatin potently lowers total and low density lipoprotein (LDL) cholesterol. Simvastatin was the first cholesterol-lowering agent that reduced total mortality in a randomised clinical trial. Simvastatin is effective at reducing total mortality, myocardial infarction, coronary mortality and the incidence of stroke or transient ischemic attack in patients with coronary heart disease and hypercholesterolemia. Simvastatin, like other statins, also has non-lipid mechanisms of action. These include anti-inflammatory effects, antiproliferative effects on smooth muscle cells and an upregulation of endothelial nitric oxide synthase. Overall, simvastatin has an excellent safety profile. Simvastatin, along with other statins, has made a significant impact on the morbidity and mortality from coronary heart disease.

AB - Simvastatin (Zocor™, Merck) is a safe and effective 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Simvastatin potently lowers total and low density lipoprotein (LDL) cholesterol. Simvastatin was the first cholesterol-lowering agent that reduced total mortality in a randomised clinical trial. Simvastatin is effective at reducing total mortality, myocardial infarction, coronary mortality and the incidence of stroke or transient ischemic attack in patients with coronary heart disease and hypercholesterolemia. Simvastatin, like other statins, also has non-lipid mechanisms of action. These include anti-inflammatory effects, antiproliferative effects on smooth muscle cells and an upregulation of endothelial nitric oxide synthase. Overall, simvastatin has an excellent safety profile. Simvastatin, along with other statins, has made a significant impact on the morbidity and mortality from coronary heart disease.

KW - Atherosclerosis

KW - LDL-cholesterol

KW - Myocardial infarction

KW - Simvastatin

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=0035002634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035002634&partnerID=8YFLogxK

U2 - 10.1517/14656566.2.1.153

DO - 10.1517/14656566.2.1.153

M3 - Article

C2 - 11336576

AN - SCOPUS:0035002634

VL - 2

SP - 153

EP - 163

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -